A Phase 3 interventional study of OMA102 and OMA102 in Female Pattern Baldness, sponsored by EMS. Not yet recruiting at 1 site in Brazil. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-02-16.
Sponsored by EMS · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Alopecia with a site in Brazil — 8 open to participants now, 8 under way, 5 of them phase 3. Alopecia · Brazil.
Among the 14 studies in Alopecia with a site in Brazil, this one has the largest planned enrollment, is the only one that started in 2025, is one of 7 in phase 3, and was the 5th registered.
512 studies on the registry are indexed under Alopecia; 128 are open to participants now.
Browse Alopecia studies →8 of the 14 studies in Alopecia with a site in Brazil are open now. Recruiting first, the newest first:
Applied Biology, Inc. · Sites in Brazil, Italy
Ages 18–65 · Women only
Clinica Dermatologica Arbache ltda · Sites in Brazil
Ages 18–65 · Men only · Healthy volunteers
EMS · Sites in Brazil
Ages 18–60 · Men only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 18–60 · Men only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 18–60 · Women only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 1
First in 2012; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 504 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 133 across the 14 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 7 most frequent:
EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.
EMS has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05824065Phase 3EMSEfficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss | 2027-01 |
| NCT07783113Farmoquimica S.A.Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use | 2027-02 |
| NCT07397325Applied Biology, Inc.Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | 2027-02-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Alopecia with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
Drug: OMA102
Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
Drug: OMA102
Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
Drug: Placebo
1 mg
2 mg
OMA102 - Placebo
Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.
Variation of hair in the mid-front area after 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.
Time frame: 6 months
Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.
Variation of hair in the mid-front area after 3 months of treatment in comparison to baseline, assessed by digital phototrichogram.
Time frame: 3 months
Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of non vellus and vellus hair growth, in the mid frontal area, assessed by digital phototrichogram.
Variation of non vellus and vellus hair in the mid-front area after 3 and 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.
Time frame: 3 and 6 months
Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception.
Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement global photographs assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception, 3 and 6 months after treatment.
Time frame: 3 and 6 months
Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Patient Global Impression, PGI-I, by the subject perception.
Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of Global Photographs assessed by Patient Global Impression PGI-I, by the investigator perception, 3 and 6 months after treatment.
Time frame: 3 and 6 months
Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL).
Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL) in comparison to baseline, 3 and 6 months after treatment.
Time frame: 3 and 6 months
Start is estimated for Jan 2025; primary completion for Jan 2027, 24 months later.
Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.